There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revance Therapeutics (RVNC – Research Report) and MiMedx Group (MDXG – Research Report) with bullish sentiments. Revance Therapeutics (RVNC) Needham analyst Serge Belanger  maintained a Buy rating on Revance Therapeutics today and set a price target of $38.00. The company’s shares closed last Monday at $30.42, close to its 52-week high of $30.95. According to TipRanks.com, Belanger is a 2-star analyst with an average return of 0.0% and a 41.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical. Revance Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.00, a 45.4% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $29.00 price target.
		  See Insiders’ Hot Stocks on TipRanks >>  MiMedx Group (MDXG) In a report released today, Swayampakula Ramakanth  from H.C. Wainwright maintained a Buy rating on MiMedx Group, with a price target of $8.00. The company’s shares closed last Monday at $3.28. According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -13.3% and a 27.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ImmunoPrecise Antibodies, Janux Therapeutics Inc, and Cellectar Biosciences. MiMedx Group has an analyst consensus of Moderate Buy, with a price target consensus of $7.50.
		  TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.  Read More on RVNC:   Indices Commodities Currencies Stocks